Engineering Papers⌕ Search

SEARCH · Engineering Papers

Results for “COMPANIES”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,729 records · Page 96

MO-D-PinS Room/Hall E-02: Multiparametric Fuctional Imaging in Radiation Therapy

MRI, with its excellent soft tissue contrast and its ability to provide physiological as well as anatomical information, is becoming increasingly used in radiation therapy for treatment planning, image-guided radiation therapy, and treatment evaluation. This session will explore solutions to integrating MRI into the simulation process. Obstacles for using MRI for simulation include distortions and artifacts, image acquisition speed, complexity of imaging techniques, and lack of electron density information. Partners in Solutions presents vendor representatives who will present their approaches to meeting these challenges and others. An increased awareness of how MRI simulation works will allow physicists to better understand and use this powerful technique. The speakers are all employees who are presenting information about their company’s products.

60 APPLIED LIFE SCIENCES↗

MO-D-PinS Room/Hall E-03: Ingenia MR-RT with MRCAT for MR-Based Radiotherapy Simulation

MRI, with its excellent soft tissue contrast and its ability to provide physiological as well as anatomical information, is becoming increasingly used in radiation therapy for treatment planning, image-guided radiation therapy, and treatment evaluation. This session will explore solutions to integrating MRI into the simulation process. Obstacles for using MRI for simulation include distortions and artifacts, image acquisition speed, complexity of imaging techniques, and lack of electron density information. Partners in Solutions presents vendor representatives who will present their approaches to meeting these challenges and others. An increased awareness of how MRI simulation works will allow physicists to better understand and use this powerful technique. The speakers are all employees who are presenting information about their company’s products.

60 APPLIED LIFE SCIENCES↗

WE-AB-BRB-00: Session in Memory of Robert J. Shalek: High Resolution Dosimetry from 2D to 3D to Real-Time 3D

Despite widespread IMRT treatments at modern radiation therapy clinics, precise dosimetric commissioning of an IMRT system remains a challenge. In the most recent report from the Radiological Physics Center (RPC), nearly 20% of institutions failed an end-to-end test with an anthropomorphic head and neck phantom, a test that has rather lenient dose difference and distance-to-agreement criteria of 7% and 4 mm. The RPC report provides strong evidence that IMRT implementation is prone to error and that improved quality assurance tools are required. At the heart of radiation therapy dosimetry is the multidimensional dosimeter. However, due to the limited availability of water-equivalent dosimetry materials, research and development in this important field is challenging. In this session, we will review a few dosimeter developments that are either in the laboratory phase or in the pre-commercialization phase. 1) Radiochromic plastic. Novel formulations exhibit light absorbing optical contrast with very little scatter, enabling faster, broad beam optical CT design. 2) Storage phosphor. After irradiation, the dosimetry panels will be read out using a dedicated 2D scanning apparatus in a non-invasive, electro-optic manner and immediately restored for further use. 3) Liquid scintillator. Scintillators convert the energy from x-rays and proton beams into visible light, which can be recorded with a scientific camera (CCD or CMOS) from multiple angles. The 3D shape of the dose distribution can then be reconstructed. 4) Cherenkov emission imaging. Gated intensified imaging allows video-rate passive detection of Cherenkov emission during radiation therapy with the room lights on. Learning Objectives: To understand the physics of a variety of dosimetry techniques based upon optical imaging To investigate the strategies to overcome respective challenges and limitations To explore novel ideas of dosimeter design Supported in part by NIH Grants R01CA148853, R01CA182450, R01CA109558. Brian Pogue is founder and president of the company DoseOptics LLC, dedicated to developing and commercializing the first dedicated Cerenkov imaging camera and system for radiation dose imaging. Work reported in this talk does not involve the use of DoseOptics technology.; H. Li, this work was supported in part by NIH Grant No. R01CA148853; S. Beddar, NIH funding R01-CA182450.

60 APPLIED LIFE SCIENCES↗

WE-AB-BRB-01: Memorial Introduction; Storage Phosphor Panels for Radiation Therapy Dosimetry

Despite widespread IMRT treatments at modern radiation therapy clinics, precise dosimetric commissioning of an IMRT system remains a challenge. In the most recent report from the Radiological Physics Center (RPC), nearly 20% of institutions failed an end-to-end test with an anthropomorphic head and neck phantom, a test that has rather lenient dose difference and distance-to-agreement criteria of 7% and 4 mm. The RPC report provides strong evidence that IMRT implementation is prone to error and that improved quality assurance tools are required. At the heart of radiation therapy dosimetry is the multidimensional dosimeter. However, due to the limited availability of water-equivalent dosimetry materials, research and development in this important field is challenging. In this session, we will review a few dosimeter developments that are either in the laboratory phase or in the pre-commercialization phase. 1) Radiochromic plastic. Novel formulations exhibit light absorbing optical contrast with very little scatter, enabling faster, broad beam optical CT design. 2) Storage phosphor. After irradiation, the dosimetry panels will be read out using a dedicated 2D scanning apparatus in a non-invasive, electro-optic manner and immediately restored for further use. 3) Liquid scintillator. Scintillators convert the energy from x-rays and proton beams into visible light, which can be recorded with a scientific camera (CCD or CMOS) from multiple angles. The 3D shape of the dose distribution can then be reconstructed. 4) Cherenkov emission imaging. Gated intensified imaging allows video-rate passive detection of Cherenkov emission during radiation therapy with the room lights on. Learning Objectives: To understand the physics of a variety of dosimetry techniques based upon optical imaging To investigate the strategies to overcome respective challenges and limitations To explore novel ideas of dosimeter design Supported in part by NIH Grants R01CA148853, R01CA182450, R01CA109558. Brian Pogue is founder and president of the company DoseOptics LLC, dedicated to developing and commercializing the first dedicated Cerenkov imaging camera and system for radiation dose imaging. Work reported in this talk does not involve the use of DoseOptics technology.; H. Li, this work was supported in part by NIH Grant No. R01CA148853; S. Beddar, NIH funding R01-CA182450.

60 APPLIED LIFE SCIENCES↗

WE-AB-BRB-02: Methods and Applications of 3D Radiochromic Dosimetry

Despite widespread IMRT treatments at modern radiation therapy clinics, precise dosimetric commissioning of an IMRT system remains a challenge. In the most recent report from the Radiological Physics Center (RPC), nearly 20% of institutions failed an end-to-end test with an anthropomorphic head and neck phantom, a test that has rather lenient dose difference and distance-to-agreement criteria of 7% and 4 mm. The RPC report provides strong evidence that IMRT implementation is prone to error and that improved quality assurance tools are required. At the heart of radiation therapy dosimetry is the multidimensional dosimeter. However, due to the limited availability of water-equivalent dosimetry materials, research and development in this important field is challenging. In this session, we will review a few dosimeter developments that are either in the laboratory phase or in the pre-commercialization phase. 1) Radiochromic plastic. Novel formulations exhibit light absorbing optical contrast with very little scatter, enabling faster, broad beam optical CT design. 2) Storage phosphor. After irradiation, the dosimetry panels will be read out using a dedicated 2D scanning apparatus in a non-invasive, electro-optic manner and immediately restored for further use. 3) Liquid scintillator. Scintillators convert the energy from x-rays and proton beams into visible light, which can be recorded with a scientific camera (CCD or CMOS) from multiple angles. The 3D shape of the dose distribution can then be reconstructed. 4) Cherenkov emission imaging. Gated intensified imaging allows video-rate passive detection of Cherenkov emission during radiation therapy with the room lights on. Learning Objectives: To understand the physics of a variety of dosimetry techniques based upon optical imaging To investigate the strategies to overcome respective challenges and limitations To explore novel ideas of dosimeter design Supported in part by NIH Grants R01CA148853, R01CA182450, R01CA109558. Brian Pogue is founder and president of the company DoseOptics LLC, dedicated to developing and commercializing the first dedicated Cerenkov imaging camera and system for radiation dose imaging. Work reported in this talk does not involve the use of DoseOptics technology.; H. Li, this work was supported in part by NIH Grant No. R01CA148853; S. Beddar, NIH funding R01-CA182450.

60 APPLIED LIFE SCIENCES↗

WE-AB-BRB-03: Real-Time Volumetric Scintillation Dosimetry for Radiation Therapy

Despite widespread IMRT treatments at modern radiation therapy clinics, precise dosimetric commissioning of an IMRT system remains a challenge. In the most recent report from the Radiological Physics Center (RPC), nearly 20% of institutions failed an end-to-end test with an anthropomorphic head and neck phantom, a test that has rather lenient dose difference and distance-to-agreement criteria of 7% and 4 mm. The RPC report provides strong evidence that IMRT implementation is prone to error and that improved quality assurance tools are required. At the heart of radiation therapy dosimetry is the multidimensional dosimeter. However, due to the limited availability of water-equivalent dosimetry materials, research and development in this important field is challenging. In this session, we will review a few dosimeter developments that are either in the laboratory phase or in the pre-commercialization phase. 1) Radiochromic plastic. Novel formulations exhibit light absorbing optical contrast with very little scatter, enabling faster, broad beam optical CT design. 2) Storage phosphor. After irradiation, the dosimetry panels will be read out using a dedicated 2D scanning apparatus in a non-invasive, electro-optic manner and immediately restored for further use. 3) Liquid scintillator. Scintillators convert the energy from x-rays and proton beams into visible light, which can be recorded with a scientific camera (CCD or CMOS) from multiple angles. The 3D shape of the dose distribution can then be reconstructed. 4) Cherenkov emission imaging. Gated intensified imaging allows video-rate passive detection of Cherenkov emission during radiation therapy with the room lights on. Learning Objectives: To understand the physics of a variety of dosimetry techniques based upon optical imaging To investigate the strategies to overcome respective challenges and limitations To explore novel ideas of dosimeter design Supported in part by NIH Grants R01CA148853, R01CA182450, R01CA109558. Brian Pogue is founder and president of the company DoseOptics LLC, dedicated to developing and commercializing the first dedicated Cerenkov imaging camera and system for radiation dose imaging. Work reported in this talk does not involve the use of DoseOptics technology.; H. Li, this work was supported in part by NIH Grant No. R01CA148853; S. Beddar, NIH funding R01-CA182450.

60 APPLIED LIFE SCIENCES↗

WE-AB-BRB-04: Cherenkov Imaging for Radiation Therapy Dose Verification On Patients

Despite widespread IMRT treatments at modern radiation therapy clinics, precise dosimetric commissioning of an IMRT system remains a challenge. In the most recent report from the Radiological Physics Center (RPC), nearly 20% of institutions failed an end-to-end test with an anthropomorphic head and neck phantom, a test that has rather lenient dose difference and distance-to-agreement criteria of 7% and 4 mm. The RPC report provides strong evidence that IMRT implementation is prone to error and that improved quality assurance tools are required. At the heart of radiation therapy dosimetry is the multidimensional dosimeter. However, due to the limited availability of water-equivalent dosimetry materials, research and development in this important field is challenging. In this session, we will review a few dosimeter developments that are either in the laboratory phase or in the pre-commercialization phase. 1) Radiochromic plastic. Novel formulations exhibit light absorbing optical contrast with very little scatter, enabling faster, broad beam optical CT design. 2) Storage phosphor. After irradiation, the dosimetry panels will be read out using a dedicated 2D scanning apparatus in a non-invasive, electro-optic manner and immediately restored for further use. 3) Liquid scintillator. Scintillators convert the energy from x-rays and proton beams into visible light, which can be recorded with a scientific camera (CCD or CMOS) from multiple angles. The 3D shape of the dose distribution can then be reconstructed. 4) Cherenkov emission imaging. Gated intensified imaging allows video-rate passive detection of Cherenkov emission during radiation therapy with the room lights on. Learning Objectives: To understand the physics of a variety of dosimetry techniques based upon optical imaging To investigate the strategies to overcome respective challenges and limitations To explore novel ideas of dosimeter design Supported in part by NIH Grants R01CA148853, R01CA182450, R01CA109558. Brian Pogue is founder and president of the company DoseOptics LLC, dedicated to developing and commercializing the first dedicated Cerenkov imaging camera and system for radiation dose imaging. Work reported in this talk does not involve the use of DoseOptics technology.; H. Li, this work was supported in part by NIH Grant No. R01CA148853; S. Beddar, NIH funding R01-CA182450.

60 APPLIED LIFE SCIENCES↗

WE-DE-201-07: Measurement of Real-Time Dose for Tandem and Ovoid Brachytherapy Procedures Using a High Precision Optical Fiber Radiation Detector

Purpose: Development of a novel on-line dosimetry tool is needed to move toward patient-specific quality assurance measurements for Ir-192 HDR brachytherapy to verify accurate dose delivery to the intended location. This work describes the development and use of a nano-crystalline yttrium oxide inorganic scintillator based optical-fiber detector capable of acquiring real-time high-precision dose measurements during tandem and ovoid (T&O) gynecological (GYN) applicator Ir-192 HDR brachytherapy procedures. Methods: An optical-fiber detector was calibrated by acquiring light output measurements in liquid water at 3, 5, 7, and 9cm radial source-detector-distances from an Ir-192 HDR source. A regression model was fit to the data to describe the relative light output per unit dose (TG-43 derived) as a function of source-detector-distance. Next, the optical-fiber detector was attached to a vaginal balloon fixed to a Varian Fletcher-Suit-Delclos-style applicator (to mimic clinical setup), and localized by acquiring high-resolution computed tomography (CT) images. To compare the physical point dose to the TPS calculated values (TG-43 and Acuros-BV), a phantom measurement was performed, by submerging the T&O applicator in a liquid water bath and delivering a treatment template representative of a clinical T&O procedure. The fiber detector collected scintillation signal as a function of time, and the calibration data was applied to calculate both real-time dose rate, and cumulative dose. Results: Fiber cumulative dose values were 100.0cGy, 94.3cGy, and 348.9cGy from the tandem, left ovoid, and right ovoid dwells, respectively (total of 443.2cGy). A plot of real time dose rate during the treatment was also acquired. The TPS values at the fiber location were 458.4cGy using TG-43, and 437.6cGy using Acuros-BV calculated as Dm,m (per TG-186). Conclusion: The fiber measured dose value agreement was 3% vs TG-43 and −1% vs Acuros-BV. This fiber detector opens up new possibilities for performing patient-specific quality assurance for Ir-192 HDR GYN procedures. Funding from Coulter Foundation, Duke Bio-medical Engineering. Company is being created around the detector technology. Duke holds patents on the technology.

60 APPLIED LIFE SCIENCES↗

TH-CD-209-09: Quickly Identifying Good Candidates for Proton Therapy From Geometric Considerations

Purpose: We developed a knowledge-based model that can predict the patient-specific benefits of proton therapy based upon geometric considerations. The model could also aid patient selection in model-based clinical trials or help justify clinical decisions to insurance companies. Methods: The knowledge-based method trains a model upon existing proton treatment plans, exploiting correlations between dose and distance-to-target. Each OAR is split into concentric subvolumes surrounding the target volume, and a skew-normal PDF is fit to the dose distribution found within each shell. The model learns from shared trends in how the best-fit skew-normal parameters depend upon distance-to-target. It can then predict feasible OAR DVHs for a new patient (without a proton plan) based upon their geometry. The expected benefits of proton therapy are assessed by comparing the predicted DVHs to those of an IMRT plan, using a metric such as the equivalent uniform dose (EUD). Results: A model was trained for clival chordoma, owing to its geometric complexity and the multitude of nearby OARs. The model was trained using 20 patients and validated with a further 20 patients, and considers several different OARs. The predicted EUD was in good agreement with that of the actual proton plan. The coefficient of determination (R-squared) was 85% overall, 92% for cochleas, 80% for optic chiasm and 79% for spinal cord. The model exhibited no signs of bias or overfitting. When compared to an IMRT plan, the model could classify whether a patient will experience a gain or a loss with an accuracy between 75% and 95%, depending upon the OAR. Conclusion: We developed a model that can quickly and accurately predict the patient-specific benefits of proton therapy in clival chordoma patients, though models could be trained for other tumor sites. This work is funded by National Cancer Institute grant U19 CA 021239.

60 APPLIED LIFE SCIENCES↗

TH-D-BRC-00: Educational Point Counter/Point: Has Photon RT Hit the Limits?

Interest in proton therapy has increased dramatically in the past couple of years, especially in the United States. There certainly is an important place for proton therapy in the arsenal of cancer treatments. Its dosimetric advantage and potential for low toxicity makes it the perfect partner for photons and other cancer treatment modalities. Often there is a belief that the new technology ought to be better but many believe that they should be widely adopted in the clinic only after evidence has shown that they are at least as safe and efficacious as existing technologies, which are often less expensive. This is the case for proton radiotherapy. This session being both educational and debate will provide a good review of basics and technological advancement as well as a comprehensive clinical update for both proton and photon therapy. Future technology developments and how they will impact the potential dosimetric advantage of proton therapy will be discussed. Particularly the debate will focus on whether these developments will close or widen the gap between photon and proton therapy. Learning Objectives: To review challenges, limitations, and recent and future developments in proton therapy. To review challenges, limitations, recent and future developments in photon radiotherapy. To review current clinical trials and challenging clinical cases. C. Yu, No company or organization that my presentation mentions provided me with financial support. I am the Founder and CEO of Xcision Medical Systems, LLC. However, my presentation will not mention any product or technology developed by Xcision.

60 APPLIED LIFE SCIENCES↗

TH-D-BRC-01: Panel Member

Interest in proton therapy has increased dramatically in the past couple of years, especially in the United States. There certainly is an important place for proton therapy in the arsenal of cancer treatments. Its dosimetric advantage and potential for low toxicity makes it the perfect partner for photons and other cancer treatment modalities. Often there is a belief that the new technology ought to be better but many believe that they should be widely adopted in the clinic only after evidence has shown that they are at least as safe and efficacious as existing technologies, which are often less expensive. This is the case for proton radiotherapy. This session being both educational and debate will provide a good review of basics and technological advancement as well as a comprehensive clinical update for both proton and photon therapy. Future technology developments and how they will impact the potential dosimetric advantage of proton therapy will be discussed. Particularly the debate will focus on whether these developments will close or widen the gap between photon and proton therapy. Learning Objectives: To review challenges, limitations, and recent and future developments in proton therapy. To review challenges, limitations, recent and future developments in photon radiotherapy. To review current clinical trials and challenging clinical cases. C. Yu, No company or organization that my presentation mentions provided me with financial support. I am the Founder and CEO of Xcision Medical Systems, LLC. However, my presentation will not mention any product or technology developed by Xcision.

60 APPLIED LIFE SCIENCES↗

TH-D-BRC-02: Panel Member

Interest in proton therapy has increased dramatically in the past couple of years, especially in the United States. There certainly is an important place for proton therapy in the arsenal of cancer treatments. Its dosimetric advantage and potential for low toxicity makes it the perfect partner for photons and other cancer treatment modalities. Often there is a belief that the new technology ought to be better but many believe that they should be widely adopted in the clinic only after evidence has shown that they are at least as safe and efficacious as existing technologies, which are often less expensive. This is the case for proton radiotherapy. This session being both educational and debate will provide a good review of basics and technological advancement as well as a comprehensive clinical update for both proton and photon therapy. Future technology developments and how they will impact the potential dosimetric advantage of proton therapy will be discussed. Particularly the debate will focus on whether these developments will close or widen the gap between photon and proton therapy. Learning Objectives: To review challenges, limitations, and recent and future developments in proton therapy. To review challenges, limitations, recent and future developments in photon radiotherapy. To review current clinical trials and challenging clinical cases. C. Yu, No company or organization that my presentation mentions provided me with financial support. I am the Founder and CEO of Xcision Medical Systems, LLC. However, my presentation will not mention any product or technology developed by Xcision.

60 APPLIED LIFE SCIENCES↗

TH-D-BRC-03: Panel Member

Interest in proton therapy has increased dramatically in the past couple of years, especially in the United States. There certainly is an important place for proton therapy in the arsenal of cancer treatments. Its dosimetric advantage and potential for low toxicity makes it the perfect partner for photons and other cancer treatment modalities. Often there is a belief that the new technology ought to be better but many believe that they should be widely adopted in the clinic only after evidence has shown that they are at least as safe and efficacious as existing technologies, which are often less expensive. This is the case for proton radiotherapy. This session being both educational and debate will provide a good review of basics and technological advancement as well as a comprehensive clinical update for both proton and photon therapy. Future technology developments and how they will impact the potential dosimetric advantage of proton therapy will be discussed. Particularly the debate will focus on whether these developments will close or widen the gap between photon and proton therapy. Learning Objectives: To review challenges, limitations, and recent and future developments in proton therapy. To review challenges, limitations, recent and future developments in photon radiotherapy. To review current clinical trials and challenging clinical cases. C. Yu, No company or organization that my presentation mentions provided me with financial support. I am the Founder and CEO of Xcision Medical Systems, LLC. However, my presentation will not mention any product or technology developed by Xcision.

60 APPLIED LIFE SCIENCES↗

TH-D-BRC-04: Panel Member

Interest in proton therapy has increased dramatically in the past couple of years, especially in the United States. There certainly is an important place for proton therapy in the arsenal of cancer treatments. Its dosimetric advantage and potential for low toxicity makes it the perfect partner for photons and other cancer treatment modalities. Often there is a belief that the new technology ought to be better but many believe that they should be widely adopted in the clinic only after evidence has shown that they are at least as safe and efficacious as existing technologies, which are often less expensive. This is the case for proton radiotherapy. This session being both educational and debate will provide a good review of basics and technological advancement as well as a comprehensive clinical update for both proton and photon therapy. Future technology developments and how they will impact the potential dosimetric advantage of proton therapy will be discussed. Particularly the debate will focus on whether these developments will close or widen the gap between photon and proton therapy. Learning Objectives: To review challenges, limitations, and recent and future developments in proton therapy. To review challenges, limitations, recent and future developments in photon radiotherapy. To review current clinical trials and challenging clinical cases. C. Yu, No company or organization that my presentation mentions provided me with financial support. I am the Founder and CEO of Xcision Medical Systems, LLC. However, my presentation will not mention any product or technology developed by Xcision.

60 APPLIED LIFE SCIENCES↗

Leverage demand-side policies for energy security

Energy security is a top priority for governments, companies, and households because energy systems and the critical functions that they support are threatened by disruptions from wars, pandemics, climate change, and other shocks (1). More often than not, governments rely on policies focused on energy supply to enhance energy security while generally ignoring demand-side possibilities. Further, the indicators traditionally used to measure energy security are also tilted toward the supply side; this fails to capture the full spectrum of vulnerability to energy crises. Energy security assessments need to reflect the wider benefits of security related interventions more accurately. To that end, we develop a systematic approach to measuring the energy security impacts of policy interventions that explicitly considers energy demand (buildings, transport, and industry). Here, we determine that demand-side actions outperform conventional supply-side approaches at making countries more resilient. Energy demand links more directly than supply to the satisfaction of critical social functions and human well-being that are at the core of energy security. Yet, demand-side perspectives tend to be neglected or underrepresented in analysis and policy debates on energy security. Factors that contribute to this supply-side bias include the traditional sectoral organization of industries and policy institutions along fuels (coal, oil, and gas) and energy forms (electric utilities) as well as the decentralized and multivaried activities characteristic of energy demand (from vehicles to household appliances to manufacturing and more), which leads to a multitude of actors and institutional fragmentation. The basic fundamentals of energy systems and markets, where demand and supply are intricately linked, have also not yet risen from vague awareness to a central organizing principle among policy-makers for structuring the energy security discourse.

29 ENERGY PLANNING, POLICY, AND ECONOMY↗

Influence of cluster defects of variable composition on the optical and radiative characteristics of oxide crystals

It is shown that oxide crystals contain cluster defects of variable composition, which cause absorption of light in the transparency region of crystals. The model based on the presence of cluster defects in oxide crystals explains well the experimental data on the thermal and radiative coloring of these crystals. It is noted that cluster defects accumulate oxygen in oxide crystals. These defects are responsible also for the photochromic effect in them. Application of the noted model made it possible to fabricate lead tungstate scintillators at North Crystals Company for the ALICE project (CERN) with almost 100% reproducibility of their operating characteristics.

75 CONDENSED MATTER PHYSICS, SUPERCONDUCTIVITY AND↗

Investigation of molecular mechanisms of action of chelating drugs on protein-lipid model membranes by X-ray fluorescence

Protein-lipid films based on the enzyme alkaline phosphatase were subjected to the action of chelating drugs, which are used for accelerating the removal of heavy metals from the human body, and the elemental composition of the resulting films was investigated. Total-reflection X-ray fluorescence measurements were performed at the Berlin Electron Storage Ring Company for Synchrotron Radiation (BESSY) in Germany. A comparative estimation of the protective effect of four drugs (EDTA, succimer, xydiphone, and mediphon) on membrane-bound enzymes damaged by lead ions was made. The changes in the elemental composition of the protein-lipid films caused by high doses of chelating drugs were investigated. It was shown that state-of-the-art X-ray techniques can, in principle, be used to develop new methods for the in vitro evaluation of the efficiency of drugs, providing differential data on their actions.

60 APPLIED LIFE SCIENCES↗

The creation of high-temperature superconducting cables of megawatt range in Russia

Urgent problems of the power industry in the 21st century require the creation of smart energy systems, providing a high effectiveness of generation, transmission, and consumption of electric power. Simultaneously, the requirements for controllability of power systems and ecological and resource-saving characteristics at all stages of production and distribution of electric power are increased. One of the decision methods of many problems of the power industry is the development of new high-efficiency electrical equipment for smart power systems based on superconducting technologies to ensure a qualitatively new level of functioning of the electric power industry. The intensive research and development of new types of electrical devices based on superconductors are being carried out in many industrialized advanced countries. Interest in such developments has especially increased in recent years owing to the discovery of so-called high-temperature superconductors (HTS) that do not require complicated and expensive cooling devices. Such devices can operate at cooling by inexpensive and easily accessible liquid nitrogen. Taking into account the obvious advantages of superconducting cable lines for the transmission of large power flows through an electrical network, as compared with conventional cables, the Federal Grid Company of Unified Energy System (JSC FGC UES) initiated a research and development program including the creation of superconducting HTS AC and DC cable lines. Two cable lines for the transmitted power of 50 MVA/MW at 20 kV were manufactured and tested within the framework of the program.

75 CONDENSED MATTER PHYSICS, SUPERCONDUCTIVITY AND↗